RECRUITING Not applicable ClinicalTrials.gov

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

Sponsor: University of Alabama at Birmingham • ClinicalTrials.gov ID: NCT07671937

Registry updated: 2026-10-07

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.

Interventions

INSPIRE (INtegrating Systematic PatIent-Reported Evaluations) (Behavioral)
The INSPIRE intervention is the systematic capture and presentation of patient-reported outcomes (geriatric assessment, patient preferences, and distance to care) within multi-disciplinary tumor boards
Capture of patient-reported outcomes (Behavioral)
Capture of patient-reported outcomes including geriatric assessment and patient preferences
Enhanced Clinician Awareness (Behavioral)
Inclusion of patients within tumor board that may have patient-reported outcomes

Eligibility criteria

Inclusion/Exclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB. Inclusion Criteria: * Inclusions Criteria- Patients: 1. aged 18 years or older; 2. with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis; 3. intention to be treated at a participating institution; 4. with verbal fluency in English or Spanish; and 5. scheduled to be discussed at MDTB. * Inclusion criteria - Clinicians: All clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation. Exclusion Criteria: * Exclusion criteria - Patients: Individuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish. * Exclusion criteria - Clinician: Clinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.

Conditions

Breast Cancer Corpus Uteri Cancer Ovary Cancer Pancreas Cancer Other Female Genital Malignant Neoplasms

Locations

University of Alabama at Birmingham — Birmingham, Alabama, United States
University of California Los Angeles (UCLA) — Los Angeles, California, United States
University of Oklahoma (OU) Health Campus — Oklahoma City, Oklahoma, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment